Moderna’s Shift to Cancer Company Lifts Stock Up 177%
The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.
We haven't written up this one. The New York Times has the full story — the link below goes straight to it.